Pablo C. M.
- Country
- Spain
- Department
- 2804:Dermatología
Research Overview
- Evaluation of Lebrikizumab Efficacy and Safety in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Phase 3 Randomized Study
- A multicenter, randomized, double-blind, placebo-controlled, Phase II platform study to assess the efficacy and safety of investigational compound(s) in patients with moderate to severe atopic dermatitis
- A Phase 3b/4 Randomized, Open-label, Efficacy Assessor-Blinded Study, to Evaluate the Efficacy and Safety of Upadacitinib for the Treatment of Adult Subjects with Moderate to Severe Atopic Dermatitis and Inadequate Response to Dupilumab (SWITCH-UP)
Data & Insights
Has run more than one trial at 17 of 124 partner sites.
Specializations
Dermatological Research
Specializes in investigating treatment approaches for atopic dermatitis, particularly focusing on advanced therapeutic interventions for moderate to severe cases.
- Chronic Skin Conditions
- Inflammatory Dermatoses
- Immune-Mediated Skin Disorders
Investigates innovative biological therapies targeting specific pathways in dermatological conditions.
Therapeutic Focus
Concentrates on evaluating novel treatment modalities for sustained clinical response in dermatological conditions, with particular emphasis on long-term management strategies.
- Biological Therapeutics
- Disease Severity Assessment
- Treatment Response Evaluation
Explores extended duration therapeutic interventions for optimal patient outcomes.
Patient Population Focus
Conducts research involving both adult and adolescent patients with dermatological conditions, emphasizing comprehensive treatment approaches.
- Age-Specific Treatment Responses
- Clinical Effectiveness Measures
- Safety Profile Assessment
Addresses therapeutic needs across different age groups affected by dermatological conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.